Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seat extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Abstract: A medicament dispenser comprises a housing having opposing first and second walls. A connecting assembly is associated with at least one of the first and second walls to facilitate connection of the first and second walls to one another. A blister pack containing the medicament is pivotally connected to the connecting assembly so as to be rotatable about the connecting assembly and about an axis of rotation substantially orthogonal to the first and second walls to facilitate movement of the blister pack from: i) a closed position in which the blister pack is substantially enclosed within the housing; and ii) an open position in which the blister pack is at least partially rotated from the housing.

Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Abstract: A divisible pharmaceutical tablet comprises an upper portion and a lower portion, the upper portion including at least one upper convex surface bordering at least one dividing notch. A ridgeline is formed between the at least one dividing notch and the at least one upper convex surface. The upper convex surface includes an apex defined at a location along the ridgeline.

Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seat extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seat extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

Abstract: An ampoule opener having a receiving body sized to accommodate a cap portion of an ampoule and a shield extending from the receiving body and being configured to lie adjacent a medicament storing portion of the ampoule when the cap portion of the ampoule is accommodated within the receiving body. The shield is rigidly related to the receiving body so as to be more resistive to bending relative to the receiving body in a direction away from a longitudinal axis of the receiving body than toward the longitudinal axis of the receiving body.

Abstract: A medicament dispenser can include a first side surface, a second side surface spaced from and substantially opposed to the first side surface, and a medicament packaging structure located between the first side surface and second side surface. A pivot structure can extend between the first side surface and the second side surface, and the medicament packaging structure can be rotatable about the pivot structure. Thus, the medicament packaging structure can be rotated from an enclosed state in which the medicament packaging structure is substantially enclosed by the first side surface and/or second side surface, to an exposed state in which the medicament packaging structure is substantially exposed from at least one of the first side surface and/or second side surface to provide user access to the medicament(s) stored in the medicament packaging structure.

Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seal extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

Abstract: A selectively frangible shipping carton for storing and shipping goods comprises at least one side wall joining a top wall and a bottom wall. A path of weakness extends around a periphery of the carton through at least a portion of the side wall. The path of weakness enables a user to manually separate the carton into at least two portions: an upper portion including the top wall and a lower portion including the bottom wall. A pair of lines of weakness extends upwardly relative to the path of weakness and terminates at or adjacent the top wall. A grip flap defined in the side wall between the pair of lines of weakness, the grip flap being graspable by the user when separating the carton into the at least two portions.

Abstract: A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.

Abstract: A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.

Abstract: The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.

Abstract: A container for storing a medicament comprises a deformable shell including at least one blister associated therewith. A unit of medicament is stored in the at least one blister. A rupturable material is coupled over an opening of the blister, the rupturable material being configured to rupture upon dispensing of the unit of medicament from the blister. An aroma discharge system is coupled to, or over the opening of, the blister, the aroma discharge system containing an aroma generating substance. The aroma discharge system is positioned such that dispensing of the unit of medicament from the blister results in discharge of the aroma from the aroma generating substance.

Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Abstract: A container for storing a medicament comprises a deformable shell including at least one blister associated therewith. A unit of medicament is stored in the at least one blister. A rupturable material is coupled over an opening of the blister, the rupturable material being configured to rupture upon dispensing of the unit of medicament from the blister. An aroma discharge system is coupled to, or over the opening of, the blister, the aroma discharge system containing an aroma generating substance. The aroma discharge system is positioned such that dispensing of the unit of medicament from the blister results in discharge of the aroma from the aroma generating substance.

Abstract: Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The method may include maximizing the in vivo potency of an atomoxetine compound in a subject by transdermally administering the atomoxetine compound to the subject. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite.

Abstract: A pharmaceutical formulation having a geometric configuration that affects the release characteristics of active agents contained therein and associated methods are provided. In one aspect, a sustained release oral dosage pharmaceutical tablet may include a first layer having a first active agent, where the first layer is disposed between two adjacent controlled release layers, at least one of the adjacent layers including at least one second active agent. The two adjacent layers are arranged such that they cover a portion of the first layer. The two adjacent layers may be separate layers or they may be joined into a single continuous layer, depending on the overall configuration and geometric design of the oral dosage form.